Faculty at School of Natural Sciences
Anindita Chakrabarty
Associate Professor
School of Natural Sciences
Contact Information
- Email: [email protected]
- Number: 91-120-3819100
- Number: Extn: 282
- Mechanisms of resistance to drugs that are either being used in clinic or under development for breast cancer patients
- Relationship between the phosphatidylinositol 3-kinase oncogene and cancer stem cells in anti-cancer drug resistance
- Role of oxidative stress-associated metabolic reprogramming in aging and aging-related diseases such as cancer
Know more: Click here
- PhD: Molecular Biology, Supervisor Dr. R Michael Roberts (National Academy Member and 2002 Wolf Prize Winner in Agriculture), School of Veterinary Medicine, University of Missouri-Columbia, Missouri, USA
- MSc: Biochemistry (specialization Molecular Biology), Ballygunge Science College, University of Calcutta, Kolkata, India
- BSc: Chemistry Honors, Vidyasagar College, University of Calcutta, Kolkata, India
- July 2021-Present: Associate Professor, Department of Life Sciences, School of Natural Sciences, Shiv Nadar Institute of Eminence, Delhi-NCR
- July 2014-June 2021: Assistant Professor, Department of Life Sciences, School of Natural Sciences, Shiv Nadar University, Delhi-NCR
- May 2014-August 2019: DBT Ramalingaswami Re-entry Fellow, Department of Life Sciences, School of Natural Sciences, Shiv Nadar University, Delhi-NCR
- 2012: Research Instructor, Vanderbilt Ingram Cancer Center, Nashville, Tennessee, USA
- 2007-2011: Postdoctoral Fellow, Laboratory of Dr. Carlos L Arteaga, Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
- 2005-2007: Postdoctoral Fellow, Laboratory of Dr. Sudhanshu K Dey, Division of Reproductive and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
- SNU Teaching award for innovative and inspirational practices: Circle of Excellence award ceremony, 2021
- SNU Opportunities of Undergraduate Research (OUR) supervision award: Circle of Excellence award ceremony, 2021
- Ramalingaswami Re-entry Fellowship award, 2013: Ministry of Science and Technology, Department of Biotechnology, India
- Susan G Komen Postdoctoral Fellowship award, 2009: The Susan G Komen for the Cure Foundation, USA
- Larry Ewing Memorial Trainee Award, 2003: The Society for the Study of Reproduction Annual Meeting, USA
- Gold Medalist (Rank 1st) in MSc in Biochemistry, 1997: University of Calcutta
- College Topper in BSc in Chemistry, 1995: Vidyasagar College, University of Calcutta
- American Association for Cancer Research
- Society for Redox Biology and Medicine
Selected Publications (*Corresponding author): (H-index: 21, i10-index: 27)
- Shayantani Chakraborty, Dibyendu Mallick, Mausumi Goswami, F Peter Guengerich, Anindita Chakrabarty*, and Goutam Chowdhury*. The Natural Products Withaferin A and Withanone from the Medicinal Herb Withania somnifera are Covalent Inhibitors of the SARS-CoV-2 Main Protease. J Nat. Prodt. 2022, 85(10), 2340-2350 Front cover page article (Citation 7)
- Anindita Chakrabarty*, Shayantani Chakraborty, Ranjini Bhattacharya, Goutam Chowdhury. Senescence-induced chemoresistance in triple negative breast cancer and evolution-based treatment strategies. Front. Oncol. https://doi.org/10.3389/fonc.2021.674354 Invited Review (Citation 16)
- Shazia Sidddiqui, Nabeel Ahmed, Anindita Chakrabarty, Goutam Chowdhury. DNA Damage by Withanone as a Potential Cause of Liver Toxicity Observed for Herbal Products of Withania somnifera (Ashwagandha). Curr. Res. Toxicol. 2021, 2, 78-81 (Citation 14)
- Nabeel Ahmed, Anindita Chakrabarty, F. Peter Guengerich, Goutam Chowdhury. Protective Role of Glutathione against Peroxynitrite-Mediated DNA Damage During Acute Inflammation. Chem. Res. Toxicol. 2020, 33(10) 2668-2674 (Citation 14)
- Tasaduq Hussain Wani, Goutam Chowdhury, Anindita Chakrabarty*. Generation of Reactive Oxygen Species is the Primary Mode of Action and Cause of Survivin Suppression by Sepantronium Bromide. RSC Med. Chem..2021, 12, 566-578 Front Cover Page Article (Citation 2)
- Anindita Chakrabarty*, Sreeraj Surendran, Neil E. Bhola, Vishnu S. Mishra, Tasaduq Husain Wani, Khemraj S. Baghel, Carlos L. Arteaga, Rohini Garg, Goutam Chowdhury. The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells. Carcinogenesis. 2019, 40(10), 1179-1190 Editor’s Choice Article. (Citation 8)
- Wani, TH, Suendran, S, Jana, A, Chakrabarty, A and Chowdhury, G. The Quinone Based Antitumor Agent Sepantronium Bromide (YM155) Causes Oxygen Independent Redox Activated Oxidative DNA Damage. Chem. Res. Toxicol. 2018, 31(7), 612-618 Front Cover Page Article. (Citation 23)
- TH Wani, S Surendran, VS Mishra, J Chaturvedi, G Chowdhury, A Chakrabarty*. Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant, is due to persistent DNA damage-response in breast cancer cells. Oncotarget. 2018, 9 (71), 33589 (Citation 14)
- Wani, TH, Chakrabarty, A, Shibata, N, Yamazaki, H, Guengerich, FP. and Chowdhury, G. The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage. Chem. Res. Toxicol. 2017, 8, 1622-1628 (Citation 39)
- Chakrabarty, A, Bhola, N, Rinehart, C, Ghosh, R, Kuba, MG, Dave, B, Chang, JC and Arteaga, CL. Trastuzumab-resistant cells continue to rely on a HER2-PI3K-Survivin axis in a FoxO-dependent manner and are sensitive to PI3K inhibitors. Cancer research. 2013, 73(3), 1190-1200 (Citation 127)
- Chakrabarty, A, Sanchez, V, Kuba, MG, Rinehart, C and Arteaga, CL Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. USA. Breast Cancer Special Feature Article. 2012, 109(8), 2718-2723 (Citation 396)
- Garrett, J, Olivares, M, Rinehart, C, Granja-Ingram, N, Sanchez, V, Chakrabarty, A, Dave, B, Cook, R, Pao, W, McKinely, E, Manning, H, Chang, J and Arteaga, C. Transcriptional and post- translational upregulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. USA.2011, 108(12), 5021-5026 (Citation 489)
- Garrett, JT, Chakrabarty, A and Arteaga, CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget. 2011, 2(12), 1314-21 (Citation 63)
- Chakrabarty, A, Rexer, BN, Wang, SE., Cook, RS, Engelman, JA and Arteaga, CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3. Oncogene. 2010, 29(37), 5193-5203 (Citation 108)
- Chakrabarty, A, Tranguch, S, Daikoku, T, Jensen, K, Furneaux, H and Dey, SK. MicroRNA regulation of Cyclooxygenase-2 during embryo implantation. Proc. Natl. Acad. Sci. USA. 2007, 104, 15144-15149 (Citation 347)
Patent:
- Dana T Aftab, Carlos L Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron-Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent. Combinations of kinase inhibitors for the treatment of cancer. US Patent 9011863. 4/21/2015
- Podcast with the ICCA India initiative, 2021
- Speaker, Emerging Trends in Translational Oncology at AIIMS, Delhi, India, 2020
- Speaker, Virtual Congress on Breast Cancer Research, 2020
- Speaker, 3rd Translational Cancer Research Symposium at Delhi State Cancer Institute, Delhi India, 2015
- Exploiting the fitness cost of transforming growth factor-β signaling pathway-dependency of chemotherapy-resistant, senescent triple negative breast cancer cells: an evolution-guided therapeutic approach. Anindita Chakrabarty (PI), DST CRG, 2023-2026 (Approved)
- Deciphering the role of the phosphatidylinositol 3-kinase oncogenic mutation in conferring anti-HER2 therapy resistance by enriching for the stem-like tumor initiating cell population in HER2 oncogene-positive breast cancer. Anindita Chakrabarty (PI), DBT Ramalingaswami Re-entry Fellowship, 2014-2019 (Completed)
- Identification of predictive biomarkers of Sepantronium bromide in triple negative breast cancers. Anindita Chakrabarty (PI), DST ECR, 2016-2019 (Completed)
- Elucidating the mechanism of teratogenicity and anti-tumor property of thalidomide. Anindita Chakrabarty (Co-PI), DST ECR, 2016-2019 (Completed)
Combinations of Kinase inhibitors for the treatment of cancer-US9,011,863B2. Date of Patent: April 21, 2015. Inventors: Dana T. Aftab, Carlos L. Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron- Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent.
- Frontiers in Oncology: Associate editor.
- BMC Cancer: Associate editor.
- Frontiers in Endocrinology, Frontiers in Medicine: Guest Associate editor.